Quality indicators in the management of bladder cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 4, 2013, Pages 492-500

  Montgomery, Jeffrey S ^a   Miller, David C ^a   Weizer, Alon Z ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CEPHALOSPORIN; EPIRUBICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN;

ABDOMINAL SURGERY; ACCREDITATION; ADJUVANT CHEMOTHERAPY; ANTIBIOTIC THERAPY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; COMPRESSION STOCKING; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DEEP VEIN THROMBOSIS; DETRUSOR MUSCLE; DISTANT METASTASIS; HEALTH CARE PERSONNEL; HEMATURIA; HUMAN; HYDRONEPHROSIS; ILEAL CONDUIT; INFECTION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOW DRUG DOSE; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE DISSECTION; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RETROGRADE PYELOGRAPHY; REVIEW; SINGLE DRUG DOSE; STAGING; SURGICAL INFECTION; THROMBOSIS PREVENTION; TRANSURETHRAL RESECTION; URINARY DIVERSION;

EID: 84877990422     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0061     Document Type: Review

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178:2314-2330.
3. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815-825.
4. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
5. Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer 1956;9:551-558.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-465; discussion 475-477.
7. Lee CT, Dunn RL, Ingold C, et al. Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology 2007;69:1068-1072.
8. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-1018.
9. Witjes JA, Compérat E, Cowan, NC, et al. European Association of Urology. Guidelines on muscle-invasive and metastatic bladder cancer. Available at: http://www.uroweb.org/gls/pdf/07-Bladder%20Cancer-LR.pdf. Accessed March 20, 2013.
10. Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57:843-849.
11. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74-76.
12. Dutta SC, Smith JA Jr, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001;166:490-493.
13. Skolarus TA, Ye Z, Montgomery JS, et al. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology 2011;78:1345-1349.
14. Clark PE, Agarwal N, Biagioli MC, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1, 2013. Available at: NCCN.org. Accessed March 19, 2013.
15. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202-205; discussion 205-206.
16. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 Pt 1):2186-2190, quiz 2435.
17. Madeb R, Golijanin D, Noyes K, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 2009;115:2660-2670.
18. Burks FN, Liu AB, Suh RS, et al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol 2012;188:2108-2113.
19. Filson C, Montgomery J, Dailey S, et al. Risk of complications of perioperative mitomycin (Mmc) among bladder cancer patients undergoing endoscopic tumor resection. J Urol 2012;187(Suppl):e676-677.
20. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-1129.
21. Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol 2011;29:59-71.
22. Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000:CD001986.
23. Margel D, Alkhateeb SS, Finelli A, Fleshner N. Diminished efficacy of bacille Calmette-Guerin among elderly patients with nonmuscle invasive bladder cancer. Urology 2011;78:848-854.
24. Schade G, Parker WR, He C, et al. Diabetes mellitus predicts poor response to induction BCG in non-muscle invasive bladder cancer. J Urol 2010;183:e520.
25. Boorjian SA, Berglund RK, Maschino AC, et al. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. J Urol 2009;182:1306-1312.
26. Hoffmann P, Roumeguere T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006;355:2705-2707.
27. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
28. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-476.
29. Dash A, Pettus JA 4th, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113:2471-2477.
30. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011;29:252-258.
31. Raj GV, Karavadia S, Schlomer B, et al. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 2011;117:276-282.
32. AUA and WOCN Society joint position statement on the value of preoperative stoma marking for patients undergoing creation of an incontinent urostomy. Wound Ostomy Continence Nurs 2009;36:267-268.
33. Silver A, Eichorn A, Kral J, et al. Timeliness and use of antibiotic prophylaxis in selected inpatient surgical procedures. The Antibiotic Prophylaxis Study Group. Am J Surg 1996;171:548-552.
34. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
35. Wolf JS Jr, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008;179:1379-1390.
36. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164-174.
37. Forrest JB, Clemens JQ, Finamore P, et al. Best practice statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol 2009;181:1170-1177.
38. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008;112:2401-2408.
39. Mitropoulos D, Artibani W, Graefen M, et al. Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol 2012;61:341-349.
40. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.